Skip to main content
. 2021 Feb 12;41(2):155–162. doi: 10.1097/JCP.0000000000001361

FIGURE 1.

FIGURE 1

Viloxazine plasma concentration-time profiles after viloxazine extended-release alone and after combination viloxazine extended-release + lisdexamfetamine on linear (A) and semilogarithmic (B) scales.

HHS Vulnerability Disclosure